Get started
Author

Riisnaes R

Observed name: R. Riisnaes
Observed institution: Institute of Cancer Research
OpenAlex ID: A5128396752
PI3K/AKT pathway deleterious mutations in lethal prostate cancer
2018 · P. Rescigno, M. Rediti, et al. · Annals of Oncology · 4
121P ATM germline mutations in lethal prostate cancer
2022 · R.M. Grochot, S. Carreira, et al. · Annals of Oncology
4P Targeting PI3K/AKT/mTOR pathway in platinum-resistant ovarian high-grade serous carcinoma: Translational analysis from the randomized phase II OCTOPUS trial
2022 · G. Giannone, D. Ennis, et al. · Annals of Oncology
PDF
A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1
2022 · S. Banerjee, G. Giannone, et al. · medRxiv
PDF
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
2022 · Fenor de la Maza MD, Chandran K, et al. · Newcastle University ePrints (Newcastle Univesity)
PDF
Characterizing CDK12-mutated prostate cancers A C
2021 · Rescigno P, Gurel B, et al. · Newcastle University ePrints (Newcastle Univesity)
HER3 Is an Actionable Target in Advanced Prostate Cancer
2021 · Gil V, Miranda S, et al. · Newcastle University ePrints (Newcastle Univesity)
PDF
Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial
2021 · Carreira S, Porta N, et al. · Newcastle University ePrints (Newcastle Univesity)
PDF
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
· Neeb A, Herranz N, et al. · Newcastle University ePrints (Newcastle Univesity)
PDF
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
· Guo C, Figueiredo I, et al. · Newcastle University ePrints (Newcastle Univesity)
PDF
Works count: 10
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type